Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

  • Teil II Symposium Über Die Wirkung Von Pharmaka Auf Die Nucleinsäuren Und Ihr Stoffwechselverhalten
  • Published:

Klinische Aspekte der Chemotherapie bösartiger Tumoren und maligner Systemerkrankungen

  • 16 Accesses

This is a preview of subscription content, log in to check access.

Literatur

  1. 1

    Adelberger, L.: Diskussionsbeitrag. Mitteilungsdienst Gesellschaft zur Bekämpfung der Krebskrankheiten, Düsseldorf, Heft 10, Bd. II, S. 831 (1963).

  2. 2

    Aisenberg, A. C.: Hodgkin's disease-prognosis, treatment, and etiologic and immunologic considerations. New Engl. J. Med. 270, 508, 565, 617 (1964).

  3. 3

    Anderson, H. E., J. D. Bisgard, and A. M. Greene: Metastatic chorioepithelioma of lung with nitrogen mustard therapy: Preliminary report. Arch. Surg. 68, 829 (1954).

  4. 4

    Ansfield, F. J., J. M. Schroeder, and A. R. Curreri: Five years clinical experience with 5-Fluorouracil. J. Amer. med. Ass. 181, 295 (1962).

  5. 5

    Armstrong, J. G., R. W. Dyke, P. J. Fouts, and J. E. Gahimer: Hodgkin's disease, carcinoma of the breast and other tumours treated with vinblastine sulfate. Cancer Chemother. Rep. 18, 49 (1962).

  6. 6

    Atkinson, J. B., J. F. Mahoney, I. R. Schwartz, and J. A. Hesch: Therapy of acute leucemia by wholebody irradiation and bone marrow transplantation in man. Blood 14, 228 (1959).

  7. 7

    Bagshawe, K. D.: Throphoblastic tumors chemotherapy and developments. Brit. med. J. 1963 II, 1303.

  8. 8

    — In: Modern Trends in Gynaecology, ed. R. J. Kellar, p. 38. London: Butterworths 1963.

  9. 9

    Beecham, C. T., A. R. Peel, and R. Robins: Nitrogen mustard and x-rays in the treatment of pulmonary metastases from choriocarcinoma. Amer. J. Obstet. Gynec. 69, 510 (1955).

  10. 10

    Bergsagel, D. E.: Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma. Cancer Chemother. Rep. 16, 261 (1962).

  11. 11

    —: Myeloma proteins and the clinical response to melphalan therapy. Science 148, 376 (1965).

  12. 12

    Bergenstal, D. M., R. Hertz, M. B. Lipsett, and R. H. Moy: Chemotherapy of adrenocortical Cancer with o,p′DDD. Ann. intern. Med. 53, 672 (1960).

  13. 13

    Berlin, N. I., D. Rall, and J. A. Mead: Folic acid antagonist. Effects on the cell and the patient. Combined clinical staff conference at the National Institutes of Health. Arch. intern. Med. 59, 931 (1963).

  14. 14

    Bernard, J., Ch. Jacquillat, M. Boiron, M. Weil et R. Soto: Traitement de la maladie de Hodgkin par la vincaleucoblastine. Presse méd. 72, 1471 (1964).

  15. 15

    —, M. Seligmann et F. Danon: de traitement de 21 malades atteints de myélome ou de macroglobulinémie par le p-di-2-chloréthyl-amino-L-phénylalanine (Melphalan). Nouv. Rev. franç. Hémat. 2, 611 (1962).

  16. 16

    Bertino, J. R.: The mechanism of action of the Folate Antagonists in man. Cancer Res. 23, 1286 (1963).

  17. 17

    Boesen, E., D. A. G. Galton, and E. Wiltshaw: Clinical results with chlorambucil, Melphalan, and 1,6-Dimesylmannitol. In Pl. A. Plattner: Chemotherapy of Cancer, p. 51. Amsterdam: Elsevier 1964.

  18. 18

    Bollag, W., and E. Grunberg: Tumor inhibitory effects of a new class of cytotoxic agents: methylhydrazine derivatives. Experientia (Basel) 19, 130 (1963).

  19. 19

    Brown, J. H., and B. J. Kennedy: Mithramycin in the treatment of disseminated testicular Neoplasms. New Engl. J. Med. 272, 11 (1965).

  20. 20

    Brennan, M. J., R. W. Talley, E. L. San Diego, J. H. Burrows, R. M. O'Bryan, V. K. Vaitkevicius, and S. Horeglad: Critical analysis of 594 cancer patients treated with 5-Fluorouracil. In Pl. A. Plattner: Chemotherapy of Cancer, p. 118. Amsterdam: Elsevier 1964.

  21. 21

    —: 5-Fluorouracil treatment of liver metastases by continuous hepatic artery infusion via Cournand catheter. Results and suitability for intensive postsurgical adjuvant chemotherapy. Ann. Surg. 158, 405 (1963).

  22. 22

    —: Quantitative studies on the growth of spontaneous tumor. International Symposium on Biological Interactions in normal and neoplastic growth, ed. M. J. Brennan and W. L. Simpson, p. 739. Boston: Little, Brown & Co. 1962.

  23. 23

    Brock, N., u. H. J. Hohorst: Über die Aktivierung von Cyclophosphamid im Warmblüterorganismus. In H. Wilmanns: Chemotherapie maligner Tumoren, S. 41. Stuttgart: Schattauer 1964.

  24. 24

    Brockman, R. W., C. Sparks, T. J. Hutchison, and H. E. Skipper: A Mechanism of resistance to 8-azaguanine. I. Microbiological studies on the metabolism of purines and 8-azapurines. Cancer Res. 19, 177 (1959).

  25. 25

    —: Decreased Tribonucleotide pyrophosphorylase activity of streptococcus faecalis and L 1210 leukemia resistant to purine antagonists. Biochem. pharmacol. 2, 77 (1959).

  26. 26

    Brockman, R. W.: A Mechanism of resistance to 6-mercaptopurine: metabolism of hypoxanthine and 6-mercaptopurine by sensitive and resistant neoplasms. Cancer Res. 20, 643 (1960).

  27. 27

    — Biochemical Aspects of Mercaptopurine Inhibition and Resistance. Cancer Res. 23, 1191 (1963).

  28. 28

    Burchenal, J. H.: Present Status of the Terephthalanilides. II. Studies on the mechanism of antileukemic action. In Pl. A. Plattner: Chemotherapy of Cancer, p. 233. Amsterdam: Elsevier 1964.

  29. 29

    — Some problems basic to Cancer Research with particular reference to Chemotherapy. Cancer Res. 23, 1186 (1963).

  30. 30

    — Problems in clinical resistance. Canad. Cancer Conference, Vol. 5, p. 449 (1963).

  31. 31

    —: Mechanisms of Resistance. Acta Un. int. Cancr. 7, 436 (1951).

  32. 32

    Carbone, P. P., E. J. Freireich, E. Frei III, P. Rall, M. Karon, and C. O. Brindley: The effectiveness of methylglyoxal-bis-guanylhydrazone in human malignant disease. Acta Un. int. Cancr. 20, 340 (1964).

  33. 33

    Chan, D. P. C.: Treatment of Chorionepithelioma with methotrexate. Brit. med. J. 1962 II, 957.

  34. 34

    Collins, V. P., R. K. Loeffler, and H. Tivey: Observations on growth rates of human tumors. Amer. J. Roentgenol. 76, 988 (1956).

  35. 35

    Curreri, A. R.: Nitrogen mustard as an adjuvant to pulmonary resection in the treatment of carcinoma of the lung. Cancer Chemother. Rep. 16, 123 (1962).

  36. 36

    — PA-144 toxicity studies. Proc. Amer. Ass. Cancer Res. 3, 103 (1960).

  37. 37

    — F. J. Ansfield: Mithramycin-human toxicology and preliminary therapeutic investigation. Cancer Chemother. Rep. 8, 18 (1960).

  38. 38

    Dameshek, W.: Einige Gedanken zum Lupus erythematodes. Med. Klin. 59, 347 (1964).

  39. 39

    Danowski, T. S., M. E. Sarver, C. Moses, and J. V. Bonessi: o—p′DDD therapy in Cushings syndrome and in obesity with cushingoid changes. Amer. J. Med. 37, 235 (1964).

  40. 40

    Davidson, J. D.: Studies on the mechanism of action of 6-mercaptopurine in sensitive and resistant L 1210 leukemia in vitro. Cancer Res. 20, 225 (1960).

  41. 41

    Denk, W.: Weitere Erfahrungen mit der Rezidiv- und Metastasenprophylaxe nach Carcinomoperationen. Klin. Med. (Wien) 13, 426 (1958).

  42. 42

    —, u. K. Karrer: Chemotherapie als Versuch einer Rückfallverhütung nach Carcinomoperationen. Krebsarzt 14, 81 (1959).

  43. 43

    Druckrey, H.: Problems of Host defense in metastases and tumor therapy: Experimental contributions. International Symposium on biological interactions in normal and neoplastic growth, p. 777. Ed. M. J. Brennan and W. L. Simpson, Boston: Little, Brown & Co. 1962.

  44. 44

    —: Experimentelle Beiträge zum Dosis-Problem in der Krebs-Chemotherapie und zur Wirkungsweise von Endoxan. Dtsch. med. Wschr. 88, 651, 715 (1963).

  45. 45

    Eichhorn, H.-J.: Die Stellung der Strahlentherapie in der Behandlung des inoperablen und des operablen Bronchialcarcinoms. Dtsch. med. Wschr. 90, 1157 (1965).

  46. 46

    Endrei, E.: Über die Behandlung von Metastasen maligner embryonaler Hodentumoren mit Nitrofurazon. Helv. chir. Acta 31, 420 (1964).

  47. 47

    Ennuyer, A., P. Bataini, J. Ridremont et J. Helary: Le Traitement des métastases pulmonaires d'embryome malin du testicule par la Nitrofurazone. Sem. Hôp. Paris 8, 273 (1960).

  48. 48

    Essen, C. F. von, M. M. Kligerman, and P. Calabresi: Radiation and 5-Fluorouracil: A controlled clinical study. Radiology 81, 1018 (1963).

  49. 49

    Ezdinli, E. Z., and L. Stutzman: Chlorambucil therapy for lymphomas and chronic lymphocytic leukemia. J. Amer. med. Ass. 191, 444 (1965).

  50. 50

    Falkson, G., and E.J. Schulz: Skin changes in patients treated with 5-Fluorouracil. Brit. J. Derm. 74, 229 (1962).

  51. 51

    Fischer, G. A.: Nutritional and amethopterin-resistant characteristics of leukemic clones. Cancer Res. 19, 372 (1959).

  52. 52

    — Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. Biochem. Pharmacol. 7, 75 (1961).

  53. 53

    Fisher, D. A., T. C. Panos, and J. C. Melby: Therapy of Adrenocortical Cancer with o,p'DDD in two children. J. clin. Endocr. 23, 218 (1963).

  54. 54

    Foulds, L.: Tumour progression and neoplastic development. In P. Emmelot and O. Mühlbock: Cellular Control Mechanisms and Cancer, p. 242. Amsterdam: Elsevier 1964.

  55. 55

    Freeman, M. V.: Fluorometric measurement of absorption, distribution and excretion of single doses of 4-Amino-10-Methyl-Pteroylglutamic Acid (Methotrexate) in man. J. Pharmacol. exp. Ther. 122, 154 (1958).

  56. 56

    Frei III, E., A. Franzino, B. I. Shnider, G. Costa, J. Colsky, C. O. Brindley, H. Hosley, J. F. Holland, G. L. Gold, and U. Johnsson: Clinical studies of vinblastine. Cancer Chemother. Rep. 12, 125 (1961).

  57. 57

    Freireich, E. J., E. Frei III, and M. Karon: Methylglyoxal-bis(guanylhydrazone): A new agent active against acute myelocytic leukemia. Cancer Chemother. Rep. 16, 183 (1962).

  58. 58

    Friedgood, Ch. E., A. L. Danza, and A. Boccabella: The effects of Nitrofurans on the normal testis and on testicular tumors. Cancer Res. 12, 262 (1952).

  59. 59

    Galton, D. A. G., L. G. Israels, J. D. N. Nabarro, and M. Till: Clinical Trials of p-(Di-2-chloroethylamino)-phenylbutyric Acid (CB 1348) in malignant lymphoma. Brit. med. J. 1955 II, 1172.

  60. 60

    Gerhartz, H.: Clinical results with cyclophosphamide and trisethylene iminoquinone. In Pl. A. Plattner: Chemotherapy of Cancer, p. 62. Amsterdam: Elsevier 1964.

  61. 61

    — Contributions to the biological and clinical effect of a methylhydrazine derivative. In Pl. A. Plattner: Chemotherapy of Cancer, p. 215. Amsterdam: Elsevier 1964.

  62. 62

    Gollin, F. F., F. J. Ansfield, and H. Vermund: Clinical studies of combined chemotherapy and irradiation in inoperable bronchogenic carcinoma. Amer. J. Roentgenol. 92, 88 (1964).

  63. 63

    — Behandlung inoperabler Bronchial-Carcinome durch Kombination von Chemotherapie und Bestrahlung. Dtsch. med. Wschr. 89, 2140 (1964).

  64. 64

    Gross, R., u. W. Wilmanns: Beiträge zur Behandlung akuter Leukosen. Dtsch. med. Wschr. 89, 1 (1964).

  65. 65

    Hakala, M. T., and T. Ishihara: Chromosome constitution and amethopterin resistance in cultured mouse cells. Cancer Res. 22, 987 (1962).

  66. 66

    —, S. F. Zakrzewski, and C. A. Nichol: Mechanism of drug resistance to amethopterin in sarcoma 180 (S-180) cells in cultures. Proc. Amer. Ass. Cancer Res. 3, 115 (1960).

  67. 67

    Hayhoe, F. G. J., and D. A. Kok: Medullary aplasia in chronic myeloid leukaemia during Busulphan therapy. Brit. med. J. 1957 II, 1468.

  68. 68

    Hayllar, B. L., A. H. O'Neal, and J. A. Dotterer: Metastatic testicular tumor treated with a maintenance dose of Nitrofurazone. J. Urol. (Baltimore) 84, 565 (1960).

  69. 69

    Heidelberger, Ch.: Biochemistry of 5-Fluorouracil. In Pl. A. Plattner: Chemotherapy of Cancer, p. 88. Amsterdam: Elsevier 1964.

  70. 70

    —, and F. J. Ansfield: Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res. 23, 1226 (1963).

  71. 71

    Heilmeyer, L.: Der gegenwärtige Stand der Chemotherapie der Neoplasien. Med. Klin. 60, 649 (1965).

  72. 72

    Hertz, R.: Dietary impairment of estrogen response in the immature monkey. Proc. Soc. exp. Biol. (N. Y.) 67, 113 (1948).

  73. 73

    — Role of factors of B-complex in estrogen metabolism. Recent Progr. Hormone Res. 2, 161 (1948).

  74. 74

    — D. M. Bergenstal, M. B. Lipsett, E. B. Price, and T. F. Hilbish: Chemotherapy of choriocarcinoma and related trophoblastic tumors in women. J. Amer. med. Ass. 168, 845 (1958).

  75. 75

    — J. Lewis, and M. B. Lipsett: Five years experience with chemotherapy of metastatic choriocarcinoma and related trophoblastic tumors in women. Amer. J. Obstet. Gynec. 82, 631 (1961).

  76. 76

    — M. B. Lipsett, and R. H. Moy: Effect of VLB on metastatic choriocarcinoma and related trophoblastic tumors in women. Cancer Res. 20, 1050 (1960).

  77. 77

    —, and W. W. Tullner: Quantitative interference with estrogen-induced tissue growth by folic acid antagonists. Endocrinology 44, 278 (1949).

  78. 78

    Higgins, G. A., O. Serlin, F. Hughes, and R. W. Dwight: The veterans administration surgical adjuvant group-interim report. Cancer Chemother. Rep. 16, 141 (1962).

  79. 79

    Hill, J. M., and E. Loeb: Treatment of leukemia, lymphoma and other malignant neoplasms with vinblastine. Cancer Chemother. Rep. 15, 41 (1961).

  80. 80

    Hirt, R.: Present status of the Terephthalanilides. I. Chemical aspects. In Pl. A. Plattner: Chemotherapy of Cancer, p. 228. Amsterdam: Elsevier 1964.

  81. 81

    —, and R. Berchtold: Biophysical studies with synthetic lecithin as a path to new chemotherapeutics. Experientia (Basel) 17, 418 (1961).

  82. 82

    — Biophysical studies with synthetic lecithin as a road to new chemotherapeutic agents. Cancer Chemother. Rep. 18, 5 (1962).

  83. 83

    Hohorst, H. J., A. Ziemann u. N. Brock: Alkylierende Substanzen im Serum und Urin nach Injektion von Cyclophosphamid. Arzneimittel-Forsch. (Drug Res.) 15, 432 (1965).

  84. 84

    Hughes, F. A., and G. A. Higgins: Veterans administration surgical adjuvant lung cancer chemotherapy study: present status. J. thorac. cardiovasc. Surg. 44, 295 (1962).

  85. 85

    Huguley, Ch. M., jr., W. R. Vogler, J. W. Lea, Ch. C. Corley jr. and M. E. Lowrey: Acute leukemia treated with divided doses of methotrexate: Arch. intern. Med. 115, 23 (1965).

  86. 86

    Hunstein, W., H.-G. Harwerth u. S. Raju: Bioptische Untersuchungen zur Frage der therapiebedingten Knochenmarkfibrosen bei der chronischen myeloischen Leukämie. Med. Klin. 60, 991 (1965).

  87. 87

    Ischizuka, N.: Chemotherapy for chorionepithelioma. Gann 47, 460 (1956).

  88. 88

    Jacobson, L. O., E. K. Marks, E. Gaston, and M. H. Block: Effect of nitrogen mustard in Erythroblastic Hyperplasia in rabbits. J. Lab. clin. Med. 34, 902 (1949).

  89. 89

    James, D. H., jr., and Ph. George: Vincristine in children with malignant solid tumors. J. Pediat. 64, 534 (1964).

  90. 90

    Johnson, I. S., J. G. Armstrong, M. Gorman, and J. G. Burnett jr.: The Vinca alkaloides: A new class of oncolytic agents. Cancer Res. 23, 1390 (1963).

  91. 91

    Johnson, R. O., W. A. Kisken, and A. R. Curreri: The response of squamous cell carcinoma to intraarterial infusion with 5-Fluorouracil. Cancer Chemother. Rep. 20, 29 (1962).

  92. 92

    —: A report upon arterial infusion with 5-Fluorouracil in 100 patients. Surg. Gynec. Obstet. 120, 530 (1965).

  93. 93

    Johnston, B., and E. T. Novales: The use of velban (vinblastine sulfate) in metastatic carcinoma of the breast. Cancer Chemother. Rep. 12, 109 (1961).

  94. 94

    Kaplan, H. S.: Some possible mechanisms of carcinogenesis. In P. Emmelot and O. Mühlbock: Cellular control mechanisms and cancer, p. 373. Amsterdam: Elsevier 1964.

  95. 95

    Karon, M. R.: Leurocristine sulfate in the treatment of acute leukemia. Proc. Amer. Ass. Cancer Res. 3, 333 (1962).

  96. 96

    Karrer, K.: Zur kombinierten cytostatischen und operativen Behandlung des Carcinoms. Arzneimittel-Forsch. (Drug Res.) 14, 859, 1059 (1964).

  97. 97

    Kaung, D. T., R. M. Whittington, M. E. Patno, and Veterans Administration Cancer Chemotherapy study group: Chemotherapy of chronic lymphocytic leukemia. Arch. intern. Med. 114, 521 (1964).

  98. 98

    Keiser, G., K. Brunner u. G. Martz: Klinische Erfahrungen mit Vincaleukoblastin (Velbe), einem neuen Cytostaticum. Schweiz. med. Wschr. 92, 486 (1962).

  99. 99

    Kenis, Y.: Contributions to the biological and clinical effect of a methylhydrazine derivative. I. Clinical observations, p. 219. In Pl. A. Plattner: Chemotherapy of Cancer. Amsterdam: Elsevier 1964.

  100. 100

    —, et P. Stryckmans: Action de la mitomycine C sur l'hématopoièse dans le cancer en phase avancée. Nouv. Rev. franç. Hémat. 4, 15 (1964).

  101. 101

    — Action de la mitomycine C dans 65 cas de tumeurs malignes. Comparison de l'effect de doses faibles, répétées et de doses „massives“. Chemotherapia (Basel) 8, 114 (1964).

  102. 102

    — and J. Leburn: Clinical trial with mitomycin C in patients with solid tumors. In Pl. A. Plattner: Chemotherapy of Cancer, p. 151. Amsterdam: Elsevier 1964.

  103. 103

    Kofman, S.: Mithramycin in treatment of disseminated cancer. Proc. Amer. Ass. Cancer Res. 4, 133 (1963).

  104. 104

    —: Mithramycin antibiotic used in cancer chemotherapy. Proc. Amer. Ass. Cancer Res. 5, 36 (1964).

  105. 105

    —, and R. Eisenstein: Mithramycin in treatment of disseminated cancer. Cancer Chemother. Rep. 32, 77 (1963).

  106. 106

    — T. J. Medrek, and R. W. Alexander: Mithramycin in treatment of embryonal cancer. Cancer 17, 938 (1964).

  107. 107

    Koller, P. C.: Chromosomes in neoplasia. In P. Emmelot and O. Mühlbock: Cellular Control Mechanisms and Cancer, p. 174. Amsterdam: Elsevier 1964.

  108. 108

    Korst, D. R., G. O. Clifford, W. M. Fowler, J. Louis, and J. Will: Multiple myeloma. II. Analysis of cyclophosphamide therapy in 165 patients. J. Amer. med. Ass. 189, 758 (1964).

  109. 109

    — E. P. Frenkel, and J. C. Nixon: Multiple myeloma. Studies of mouse plasma cell tumor and human myeloma responsiveness to cyclophosphamide (cytoxan). Ann. intern. Med. 60, 217 (1964).

  110. 110

    Krokowski, E.: Die Verdopplungszeit von bösartigen Tumoren — ihr Wert für die Krebsbekämpfung. Wien. klin. Wschr. 77, 258 (1965).

  111. 111

    Kyle, R. A., R. S. Schwarz, H. L. Oliner, and W. Dameshek: A syndrome resembling adrenal cortical insufficiency associated with long term busulfan (Myleran) therapy. Blood 18, 497 (1961).

  112. 112

    Langdon, E. A., R. E. Ottoman, D. B. Rochlin, and Ch. R. Smart: Early results of combined radiation and chemotherapy in treatment of malignant tumors. Radiology 81, 1008 (1963).

  113. 113

    Leake, E., W. G. Smith, and H. J. Woodcliff: Diffuse interstitial pulmonary fibrosis after busulphan therapy. Lancet 1963, II, 432.

  114. 114

    Levin, R. H., G. M. Brittin, and E. J. Freireich: Different patterns of remission in acute myelocytic leukemia. A comparison of the effects of methylglyoxal-bis-guanylhydrazone and 6-mercaptopurine. Blood 21, 689 (1963).

  115. 115

    — E. Henderson, M. Karon, and E. J. Freireich: Treatment of acute leukemia with methylglyoxal-bis-guanylhydrazone (methyl GAG). Clin. Pharmacol. 6, 31 (1965).

  116. 116

    Li, M. C., R. Hertz, and D. B. Spencer: Effect of methotrexate upon choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. New Engl. J. Med. 259, 66 (1958).

  117. 117

    Martin, J., and N. Compston: Vincristine sulphate in the treatment of lymphoma and leukemia. Lancet 1963, 1080.

  118. 118

    Martz, G.: Clinical results with a methylhydrazine derivative. In Pl. A. Plattner: Chemotherapy of Cancer, p. 199. Amsterdam: Elsevier 1964.

  119. 119

    —, u. G. Keiser: Chemotherapie des metastasierenden chorialen Carcinoms. Oncologia (Basel) 14, 202 (1961).

  120. 120

    Masterson, J. G.: The adjuvant chemotherapy study in cancer of the ovary. Cancer Chemother. Rep. 16, 135 (1962).

  121. 121

    Mathé, G., J. L. Amiel et J. Niemetz: Greffe de moelle osseuse après irradiation totale chez des souris leucémiques suivie de l'administration d'un antimitotique pour réduire la fréquence du syndrome secondaire et ajouter à l'effet antileucémique. C. R. Acad. Sci. (Paris) 254, 3603 (1962).

  122. 122

    — J. L. Amiel L. Schwarzenberg, A. Cattan, and M. Schneider: Haematopoietic chimera in man after allogenic (homologous) bone marrow transplantation. Control of the secondary syndrome specific tolerance due to the chimerism. Brit. med. J. 1963 II, 1633.

  123. 123

    — J. L. Amiel L. Schwarzenberg A. Cattan M. Schneider The treatment of acute leukemias. In Pl. A. Plattner: Chemotherapy of Cancer, p. 99. Amsterdam: Elsevier 1964.

  124. 124

    — J. Bernard, L. Schwarzenberg, M. J. Larrieu, Cl. Lalanne, P. Denoix, J. Surmont, I. Schwarzmann et B. Ceoara: Essai de traitement de sujets atteints de leucémie aigue en rémission par l'irradiation totale suivie de transfusion de moelle osseuse homologue. Rev. franç. Étud. clin. biol. 4, 675 (1959).

  125. 125

    — J. Bernard M. J. de Vries, L. Schwarzenberg, M. J. Larrieu, Cl. Lalanne, A. Dutreix, J. L. Amiel et J. Surmont: Nouveaux essais de greffe de moelle osseuse homologue après irradiation totale chez des enfants atteints de leucémie aigue en rémission. Le problème du syndrome secondaire chez l'homme. Rev. franç. Hémat. 15, 115 (1960).

  126. 126

    — M. Schneider, A. Cattan, J. L. Amiel, and Schwarzenberg: Clinical trials with methylglyoxal-bis-(guanylhydrazone) and with N-isopropyl-α-(2-Methylhydrazino)-p-Toluamide in various leukemias and hematosarcomas. In Pl. A. Plattner: Chemotherapy of Cancer, p. 204. Amsterdam: Elsevier 1964.

  127. 127

    — O. Schweissguth, G. Brulé, J. L. Amiel, A. Cattan, M. Thomas et P. Zamet: Essai du traitement de la maladie de Hodgkin et d'autres affections réticulohistiocytaires malignes par la vincaleukoblastine. Presse méd. 70, 1349 (1962).

  128. 128

    M. Schneider, J. L. Amiel, L. Berumen, G. Brulé, A. Cattan, and L. Schwarzenberg: Methyl-Hydrazine in treatment of Hodgkin's disease and various forms of Haematosarcoma and Leucaemia. Lancet 1963, 1077.

  129. 129

    Mendelsohn, M. L.: Chronic infusion of tritiated Thymidine into mice with tumors. Science 135, 213 (1962).

  130. 130

    Miller, E.: Arterial infusion in cancer chemotherapy. In Pl. A. Plattner: Chemotherapy of Cancer, p. 251. Amsterdam: Elsevier 1964.

  131. 131

    Misra, D. K.: A direct assay for dihydrofolate reductase in human leukocytes. Blood 23, 572 (1964).

  132. 132

    Moeschlin, S.: Diagnose, Verlauf und Therapie des Morbus Hodgkin. Schweiz. med. Wschr. 94, 665 (1964).

  133. 133

    — Zeitgemäße Behandlung der Leukosen. Schweiz. med. Wschr. 95, 221, 268 (1965).

  134. 134

    —, u. E. Jubin: Die Dauertherapie des multiplen Myeloms mit p-di-(2-chloräthyl)amino-L-phenylalanin (Melphalan). Praxis 53, 1471 (1964).

  135. 135

    Molnar, G. D., V. R. Mattox, and R. C. Bahn: Clinical and therapeutic observations in the adrenal cancer: a report on 7 patients treated with o,p′-DDD. Cancer 16, 259 (1963).

  136. 136

    Montgomery, D. A. D., and R. B. Welbourn: Adrenocortical carcinoma treated with o,p′-DDD. Brit. med. J. 1965 I, 1356.

  137. 137

    Monto, R. W., A. Ten Pas, J. D. Battle jr., R. J. Rohn, J. Louis, and N. B. Louis: A-8103 in polycythemia. J. Amer. med. Ass. 190, 833 (1964).

  138. 138

    Nelson, M. M., and H. M. Evans: Pteroylglutamic acid and reproduction in the rat. J. Nutrit. 38, 11 (1949).

  139. 139

    Nelson, W. O., and E. Steinberger: The effect of therapeutic dosages of Nitrofurantoin (Furadantin) upon spermatogenesis in man. J. Urol. (Baltimore) 77, 275 (1957).

  140. 140

    — The effect of Furadroxyl upon the testis of the rat. Anat. Rec. 112, 367 (1952).

  141. 141

    Nelson, A. A., and G. Woodard: Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis (parachlorophenyl)-1, 1-dichloroethane (DDD or TDE). Arch. Path. 48, 387 (1949).

  142. 142

    Netto, A. Da S. C., B. L. Wajchenberg, C. Ravaglia, v. G. Pereira, J. Shnaider, A. A. Pupo, and A. B. De u. Cintra: Treatment of adrenocortical cancer with o,p′-DDD. Ann. intern. Med. 59, 74 (1963).

  143. 143

    Nyström, C.: Chemotherapy in malignant gynaecologic Tumours. Acta radiol. (Stockh.) 58, 257 (1962).

  144. 144

    —, and I. Stener: Methotrexate therapy in two cases of throphoblastic tumours of the uterus involving the lungs. Acta radiol. (Stockh.) 2, 401 (1964).

  145. 145

    Obrecht, P.: Vinca alkaloids. In Pl. A. Plattner: Chemotherapy of Cancer, p. 165. Amsterdam: Elsevier 1964.

  146. 146

    — Klinische Erfahrungen mit dem neuen zyklischen Phosphamidester Endoxan. Sonderb. Strahlentherapie 41, 358 (1959).

  147. 147

    — G. Mössner, K. H. Strickstrock u. J. W. Woenckhaus: Die Therapie der Lymphogranulomatose und des Reticulosarkoms mit dem Cytostaticum Velbe. Klinische und bakteriologische Untersuchungen. In W. Keiderling: Beiträge zur Inneren Medizin, S. 537. Stuttgart: Schattauer 1964.

  148. 148

    Oehme, J.: Die Therapie der akuten Leukämie bei Kindern. Dtsch. med. Wschr. 90, 1630 (1965).

  149. 149

    Oettgen, H. F., P. Clifford, and J. H. Burchenal: Malignant lymphoma involving the jaw in African children. Treatment with methotrexate. Cancer 16, 616 (1963).

  150. 150

    Oettgen, H. F., P. Clifford, and J. H. Burchenal: Malignant lymphoma involving the jaw in African children. Treatment with 2-Chloro-4′,4″-di-2-imidazolin-2-ylterephthalanilide dihydrochloride. Cancer Chemother. Rep. 27, 45 (1963).

  151. 151

    — and D. Burkitt: Malignant lymphoma involving the jaw in African children: Treatment with alkylating agents and Actinomycin D. Cancer Chemother. Rep. 28, 25 (1963).

  152. 152

    Oliner, H. R., F. Schwarz, F. Rubio, and W. Dameshek: Interstitial pulmonary fibrosis following busulfan therapy. Amer. J. Med. 31, 134 (1961).

  153. 153

    Parker, G. W., D. S. Wiltsie, and C. B. Jackson jr.: Clinical evaluation of PA-144 (Mithramycin) in solid tumors of adults. Cancer Chemother. Rep. 8, 23 (1960).

  154. 154

    Paterson, A. R. P.: Biochemical mechanisms of resistance to antimetabolits. Canad. Cancer Conference 5, 417 (1963).

  155. 155

    Petrides, P., u. U. Moncke: Ein Beitrag zur Therapie des Plasmocytoms. Verh. dtsch. Ges. inn. Med. 65, 211 (1959).

  156. 156

    Philips, F. S., St. S. Sternberg, A. P. Cronin, and P. M. Vidal: Cyclophosphamide and urinary bladder toxicity. Cancer Res. 21, 1577 (1961).

  157. 157

    Politano, V. A., G. W. Leadbetter, and W. F. Leadbetter: Use of furacin in treatment of testicular tumors: a case report. J. Urol. (Baltimore) 79, 771 (1958).

  158. 158

    Potter, V. R.: Sequential blocking of metabolic pathways in vivo. Pro. Soc. exp. Biol. (N. Y.) 76, 41 (1951).

  159. 159

    Prior, J. T., and J. H. Ferguson: Cytotoxic effects of a nitrofuran on rat testis. Cancer 3, 1062 (1950).

  160. 160

    Regelson, W., and J. F. Holland: Clinical experience with methylglyoxalbis (guanylhydrazone) dihydrochloride: A new agent with clinical activity in acute myelocytic leukemia and the lymphomas. Cancer Chemother. Rep. 27, 15 (1963).

  161. 161

    — Clinical study of parental methyl-GAG diacetate. Cancer Chemother. Rep. 11, 81 (1961).

  162. 162

    Rieder, H.: Die langjährige Mylerantherapie und ihre Nebenwirkungen. Proc. 7th congr. Europ. soc. Haemat. part. II, 308 (1960). London 1959.

  163. 163

    Rutishauser, A., and W. Bollag: Cytological investigations with a new class of cytologic agents: methylhydrazine derivatives. Experientia (Basel) 19, 131 (1963).

  164. 164

    Schmidt, C. G.: Hämorrhagische Zystitis im Verlaufe zytostatischer Therapie. Med. Welt 1963, 306.

  165. 165

    — Cytostatische Antibiotika. Ergebn. inn. Med. Kinderheilk. 20, 284 (1963).

  166. 166

    — Preliminary report on combined chemotherapy with mitomycin C and cyclophosphamide. In Pl. A. Plattner: Chemotherapy of Cancer, p. 162. Amsterdam: Elsevier 1964.

  167. 167

    Schoeniger, E. L., P. R. Salerno, and H. L. Friedell: Studies on the combined effect of Actinomycin D and x-radiation. Radiology 79, 310 (1962).

  168. 168

    Sheehan, H. L., V. K. Summers, and J. Nichols: DDD therapy in Cushing's syndrome. Lancet 1953 I, 312.

  169. 169

    Sullivan, R. D.: Continuous arterial infusion cancer chemotherapy. Surg. Clin. N. Amer. 42, 365 (1962).

  170. 170

    Spear, P. W.: Clinical trial with mithramycin. Cancer Chemother. Rep. 29, 109 (1963).

  171. 171

    Spechter, H.-J.: Die intraarterielle Infusion von Zytostatika beim Uterusund Vaginalcarcinom. Geburtsh. Frauenheilk. 25, 502 (1965).

  172. 172

    Spechter, H.-J., K. M. Bauer, O. Müller u. H. Traut: Folgen am harnbereitenden und harnableitenden System während Cyclophosphamid-Therapie. Dtsch. med. Wschr. 90, 1458 (1965).

  173. 173

    Speed, D. E., D. A. G. Galton, and A. Swan: Melphalan in treatment of myelomatosis. Brit. med. J. 1964I, 1664.

  174. 174

    Sträuli, P.: Die Bösartigkeit von Tumoren in klinischer, pathologisch-anatomischer und experimenteller Sicht. Schweiz. med. Wschr. 95, 113 (1965).

  175. 175

    Szczukowski, M. J., A. L. Daywitt, and H. Elrick: Metastatic testicular tumor treated with Nitrofurazone. J. Amer. med. Ass. 167, 1066 (1958).

  176. 176

    Tan, C. T. C., H. W. Dargeon, and J. H. Burchenal: The effect of Actinomycin D on cancer in childhood. Pediatrics 24, 544 (1959).

  177. 177

    Thomas, E. D., H. L. Lochte, J. H. Lannon, O. D. Sahler, and J. W. Ferrebee: Supraletal whole-body irradiation and isologous marrow transplantation in man. J. clin. Invest. 38, 1709 (1959).

  178. 178

    Törnblom, N.: Administration of DDD [2,2-bis(parachlorophenyl)-1,1-dichloroethane] to diabetics with hyaline vascular changes and Hyperpolysaccharidemia. Preliminary report. Acta med. scand. 154, 83 (1956).

  179. 179

    Vaitkevicius, V. K., R. W. Talley, J. L. Tucker jr., and M. J. Brennan: Cytological and clinical observations during vincaleukoblastine therapy of disseminated cancer. Cancer 15, 294 (1962).

  180. 180

    Verdon, T. A., J. Bruton, R. H. Herman, and W. R. Beisel: Clinical and chemical response of functioning adrenal cortical carcinoma to ortho, para-DDD. Metabolism 11, 226 (1962).

  181. 181

    Vogler, W. R., Ch. M. Hugeley, and W. Kerr: Toxicity and antitumor effect of divided dosis of methotrexate. Arch. intern. Med. 115, 285 (1965).

  182. 182

    Waldenström, J.: Melphalan therapy in myelomatosis. Brit. med. J. 1964I, 859.

  183. 183

    Welch, A. D.: The problem of drug resistance in cancer chemotherapy. Cancer Res. 19, 359 (1959).

  184. 184

    —: Mechanismen und Probleme bei der selektiven Chemotherapie. Dtsch. med. Wschr. 90, 1556 (1965).

  185. 185

    Whitelaw, D. M., and J. M. Teasdale: Vincaleukoblastine in the treatment of malignant disease. Canad. med. Ass. J. 85, 584 (1961).

  186. 186

    Whitmore, W. F.: Some experiences with retroperitoneal lymphnode dissection and chemotherapy in the management of testis neoplasms. Brit. J. Urol. 34, 436 (1962).

  187. 187

    Woodliff, H. J.: In-vitro sensitivity tests of leukaemic cells to chemotherapeutic agents. Med. J. Aust. 1, 512 (1964).

  188. 188

    Wright, T. L., J. Hurley, D. R. Korst, R. W. Monto, J. R. Rohn, J. J. Will, and J. Louis: Vincablastine in neoplastic disease. Cancer Res. 23, 169 (1963).

  189. 189

    Wurnig, G., P. Scheuba u. K. Karrer: Vorläufige Ergebnisse der chemotherapeutischen Rezidivprophylaxe mit Mitomen beim operierten Bronchuscarcinom. Acta Un. int. Cancr. 16, 935 (1960).

  190. 190

    Zimmermann, B., H. S. Bloch, W. L. Williams, C. R. Hitchcock, and B. Hoelscher: The effects of DDD[1,1-dichloro-2,2-bis-(p-chlorophenyl)-ethane] on the human adrenal. (Attempts to use an Adrenal-Destructive Agent in the Treatment of Disseminated Mammary and Prostatic Cancer.) Cancer 9, 940 (1956).

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schmidt, C.G. Klinische Aspekte der Chemotherapie bösartiger Tumoren und maligner Systemerkrankungen. Naunyn - Schmiedebergs Arch 253, 176–206 (1966). https://doi.org/10.1007/BF00259318

Download citation